Study of PET imaging and blood tests for ER+ HER2- metastatic breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new imaging technique (18F-FES PET/CT) along with blood markers to guide treatment for metastatic breast cancer that is ER-positive and HER2-negative. It's for people whose cancer progressed on first-line hormone therapy and who are starting a second line of hormone therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic breast cancer that is ER-positive (≥10% of cells) and HER2-negative.
- You have been on first-line hormone therapy with an aromatase inhibitor and a CDK4/6 inhibitor, and your cancer progressed after at least 6 months.
- You are eligible for a second course of hormone therapy (as decided by your doctor).
- You have not had any chemotherapy for metastatic disease, and you have not taken drugs like fulvestrant or experimental SERDs.
- You have a life expectancy of more than 3 months, are in fairly good health (ECOG 0-2), and have a tumor sample available for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special imaging scan called 18F-FES PET/CT to help doctors plan treatment and check how well it works for breast cancer that is ER-positive (meaning the cancer cells grow in response to estrogen). It may help improve treatment choices and monitoring.
This study tests whether a special PET scan and a blood test can help predict how well hormone therapy will work for people with metastatic breast cancer. The goal is to find better ways to personalize treatment.
This trial uses a special PET scan called 4FMFES-PET to take detailed pictures of ER-positive breast cancer that has spread. It helps doctors see where the cancer is and how active it is, which may guide treatment decisions.
This trial tests a special PET scan called FES to see if it can detect estrogen receptors in brain metastases. It may help doctors better target treatment for people with ER+ breast cancer that has spread to the brain.
This study tests whether a new type of PET/MRI scan can help doctors see how well breast cancer treatment is working. It is a platform study, meaning it can evaluate different treatments, but the focus is on using this advanced imaging to monitor response.
This trial tests whether a special PET scan (FDG PET-CT) can better track how well treatment is working for people with advanced breast cancer. It may help doctors choose the best therapy and monitor response over time.
Hear when a new Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.